319.40 -0.04 (-0.01%)
After hours: 6:04PM EST
|Bid||310.53 x 1000|
|Ask||323.50 x 900|
|Day's Range||310.99 - 321.11|
|52 Week Range||249.17 - 388.67|
|Beta (3Y Monthly)||1.99|
|PE Ratio (TTM)||20.88|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.
Pfizer on Friday joined a slew of pharmaceutical stocks with licensing deals to launch a Humira biosimilar under a deal with AbbVie.
In November, of the total eight analysts covering Sangamo Therapeutics (SGMO), five have given the stock a “buy” or higher rating and three analysts have given it a “hold” rating. The mean rating for Sangamo Therapeutics stock is 2.0 with a target price of $22.71, implying an upside potential of 90.5% over the closing price of $11.92 on November 29.
Sangamo Therapeutics (SGMO) focuses on developing and bringing to market novel genomic therapies. Its genome editing and gene regulation technology platform is enabled by engineering transcription factors called zinc finger DNA-binding proteins, which can increase or decrease gene expression or gene regulation.
Sangamo Therapeutics (SGMO) incurred general and administrative expenses of $10.99 million in the third quarter of 2018, compared with $6.42 million in the third quarter of 2017. The fiscal 2018 research and development expenses for peers Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) are expected at $3.52 billion, $2.48 billion, and $3.71 billion, respectively. Sangamo Therapeutics’ net interest and other income grew from $681,000 in the third quarter of 2017 to $3.4 million in the latest quarter.
Should you immediately sell a stock when it breaks out but closes beneath the proper buy point? Not always. Here are some tips on when to sit tight and when to bail early.
Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.
It's generally accepted that health care is considered one of the top defensive sectors. Warning! GuruFocus has detected 6 Warning Signs with UNH. One large-cap stock that stands out is UnitedHealth Group (UNH).
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren’t usually symmetrically distributed and index […]
United Therapeutics (UTHR) generated net revenues of $412.7 million in the third quarter—compared to $445.5 million during the third quarter of 2017, which reflected a decline of ~7% YoY (year-over-year). United Therapeutics’ net revenues during the first nine months of 2018 were $1.25 billion—compared to $1.26 billion during the same period in 2017, which reflected a decline of 1% YoY.
On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA). According to the agreement, Arena Pharmaceuticals will provide United Therapeutics exclusive worldwide rights to develop, manufacture, and commercialize its investigational drug, ralinepag, to treat individuals with pulmonary arterial hypertension. Currently, ralinepag is in its Phase 3 clinical stage.
Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back. Among the first to react was pharmacy benefits manager Express Scripts, which helps U.S. employers manage workers' prescription costs. Its chief medical officer, Steve Miller, told Reuters he "loves the science" behind Novartis's therapy, a potential cure for newborns who are diagnosed early.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back. The Swiss drugmaker's assessment of AVXS-101's value for treating spinal muscular atrophy (SMA) has put the company front-and-centre in the debate over what "super drugs", for rare diseases afflicting relatively few patients, are really worth. Among the first to react was pharmacy benefits manager Express Scripts, which helps U.S. employers manage workers' prescription costs.
Consider Gilead Sciences (GILD) and Celgene (CELG) for example. At recent prices of $70 and $75, they traded at market values that aren’t too far above the value of their operating businesses, according to discounted cash flow analysis by Jefferies biotech analyst Michael Yee and his team. Then add if they fall back to their “free pipeline” stock prices.
More and more rare-disease medications have been approved in recent years, but a tangle of complications can keep promising but expensive therapies out of reach for patients.
Pharma stocks can serve as a profitable addition to investment portfolios. With 10,000 baby boomers aging into Medicare every day, and a Medicare Part D drug plan to subsidize the cost, demographics and government subsidies has created a virtuous cycle for healthcare stocks. As a result, some have seen price levels that its profits (assuming they exist) cannot sustain. Additionally, biotech stocks are inherently risky due to the process of drug development and approval.